The present study expanded on initial development (Huang et al. 2016) by testing 114 HER2-negative patient tumor samples to confirm that a clinically significant subset of HER2−/HSFs+ tumors exists and to establish a robust determination of the cutoff value for normal versus abnormal HER2 signaling in breast cancer patient cells. This evidence concerns the gene ERBB2 and neoplasm.